[Click eStock] "SK Biopharm, Accelerating Sales Growth of Epilepsy Drug 'Xcopri'"

Sangsangin Securities forecasted on the 17th that SK Biopharm will continue its growth trend, supported by the rapid sales growth of the epilepsy treatment drug 'Xcopri' (the U.S. sales name for Cenobamate).

SK Biopharm Xcopri (the US brand name of Cenobamate)

Ha Taegi, a bio-specialized analyst at Sangsangin Securities, estimated, "U.S. sales of Xcopri in the second quarter of this year will reach 99 billion KRW, a 56% increase compared to the same period last year." He added, "Despite a 6% price increase for Xcopri earlier this year, local sales volume increased," and analyzed, "Xcopri's high growth has entered a phase where operating profit is significantly increasing."

Analyst Ha stated, "SK Biopharm has completed Phase 3 clinical trials to expand the sales regions in Asia including Korea, China, and Japan, as well as to broaden the eligible age group for Cenobamate's generalized tonic-clonic seizures (PGTC), and plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) next year." He predicted, "If approved, it will act as a factor for sales growth."

He also mentioned, "In addition, the company is pursuing a plan to introduce new central nervous system (CNS) drugs as early as this year or by next year at the latest," and conveyed, "In the long term, SK Biopharm will select the three future modalities?radiopharmaceutical therapy (RPT), targeted protein degradation technology (TPD), and cell and gene therapy (CGT)?and announce specific development plans within this year."

This content was produced with the assistance of AI translation services.